3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Breast
3
Thoracic
2
Sarcoma
2
Gynecologic
2
Genitourinary
2
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
21
Cyclophosphamide
18
fludarabine
8
Radiotherapy
8
Radiosurgery
7
Nivolumab
7
poly ICLC
6
fludarabine phosphate
6
aldesleukin
6
Therapeutics
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
durvalumab
5
Psychiatric Rehabilitation
5
Interleukin-2
5
Drug Therapy
5
Docetaxel
5
Cisplatin
5
temsirolimus
4
cemiplimab
4
Trastuzumab
4
Temozolomide
4
Sirolimus
4
Gemcitabine
4
Flow Cytometry
4
Filgrastim
4
Carboplatin
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
alectinib
×
Dermatologic
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts